Resolian
Resolian is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
Sponsor Ribocure Pharmaceuticals AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Resolian?
The 2026-10-09 snapshot links Resolian to 5 distinct CTIS trials. Recorded services include Laboratory services, Bioanalysis Lab for PK and ADA. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Resolian?
The most frequently recorded therapeutic areas are Blood Disorders, Haematological Malignancies, Hepatology, Infectious Disease. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Resolian conducted?
The linked trials record locations in 12 countries, including Bulgaria, France, Romania, Austria, Czechia. These are trial locations, not confirmed office locations or countries where Resolian delivered services.
What can this page tell me about Resolian's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Resolian. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Resolian